Principal Financial Group’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.5M | Sell |
1,420,083
-58,403
| -4% | -$1.2M | 0.02% | 647 |
|
|
2026
Q1 | $28.4M | Sell |
1,478,486
-45,637
| -3% | -$908K | 0.02% | 717 |
|
|
2025
Q4 | $25.2M | Buy |
1,524,123
+252,933
| +20% | +$4.27M | 0.01% | 760 |
|
|
2025
Q3 | $18.5M | Buy |
1,271,190
+198,207
| +18% | +$2.85M | 0.01% | 911 |
|
|
2025
Q2 | $15M | Sell |
1,072,983
-8,595
| -0.8% | -$121K | 0.01% | 1022 |
|
|
2025
Q1 | $14.7M | Sell |
1,081,578
-49,385
| -4% | -$946K | 0.01% | 1036 |
|
|
2024
Q4 | $23M | Sell |
1,130,963
-107,513
| -9% | -$2.75M | 0.01% | 768 |
|
|
2024
Q3 | $36.1M | Buy |
1,238,476
+149,939
| +14% | +$3.72M | 0.02% | 575 |
|
|
2024
Q2 | $25.3M | Sell |
1,088,537
-33,999
| -3% | -$653K | 0.02% | 728 |
|
|
2024
Q1 | $23M | Buy |
1,122,536
+48,832
| +5% | +$918K | 0.01% | 828 |
|
|
2023
Q4 | $23M | Buy |
1,073,704
+393,626
| +58% | +$7.8M | 0.01% | 794 |
|
|
2023
Q3 | $14M | Sell |
680,078
-6,414
| -0.9% | -$163K | 0.01% | 1022 |
|
|
2023
Q2 | $20.3M | Buy |
686,492
+197,531
| +40% | +$5.55M | 0.01% | 837 |
|
|
2023
Q1 | $11.3M | Sell |
488,961
-37,498
| -7% | -$1.03M | 0.01% | 1195 |
|
|
2022
Q4 | $14.6M | Sell |
526,459
-19,412
| -4% | -$578K | 0.01% | 1026 |
|
|
2022
Q3 | $16.8M | Buy |
545,871
+278,139
| +104% | +$9.04M | 0.01% | 889 |
|
|
2022
Q2 | $7.88M | Sell |
267,732
-1,272
| -0.5% | -$33.3K | 0.01% | 1377 |
|
|
2022
Q1 | $8.65M | Sell |
269,004
-61,271
| -19% | -$2.11M | 0.01% | 1457 |
|
|
2021
Q4 | $14.7M | Buy |
330,275
+26,448
| +9% | +$1.25M | 0.01% | 1166 |
|
|
2021
Q3 | $15.3M | Sell |
303,827
-25,517
| -8% | -$1.44M | 0.01% | 1140 |
|
|
2021
Q2 | $25.8M | Sell |
329,344
-8,223
| -2% | -$509K | 0.02% | 761 |
|
|
2021
Q1 | $19.3M | Buy |
337,567
+130,063
| +63% | +$8.71M | 0.01% | 944 |
|
|
2020
Q4 | $17.4M | Buy |
207,504
+4,959
| +2% | +$300K | 0.01% | 867 |
|
|
2020
Q3 | $7.26M | Buy |
202,545
+523
| +0.3% | +$15.8K | 0.01% | 1262 |
|
|
2020
Q2 | $4.88M | Sell |
202,022
-2,231
| -1% | -$52.5K | ﹤0.01% | 1435 |
|
|
2020
Q1 | $3.58M | Sell |
204,253
-20,656
| -9% | -$431K | ﹤0.01% | 1419 |
|
|
2019
Q4 | $3.92M | Buy |
224,909
+6,146
| +3% | +$102K | ﹤0.01% | 1594 |
|
|
2019
Q3 | $3.35M | Sell |
218,763
-1,354
| -0.6% | -$25.9K | ﹤0.01% | 1625 |
|
|
2019
Q2 | $4.57M | Buy |
220,117
+33,357
| +18% | +$747K | ﹤0.01% | 1558 |
|
|
2019
Q1 | $4.34M | Buy |
186,760
+810
| +0.4% | +$16.9K | ﹤0.01% | 1589 |
|
|
2018
Q4 | $3.84M | Sell |
185,950
-17
| -0% | -$308 | ﹤0.01% | 1590 |
|
|
2018
Q3 | $4.04M | Buy |
185,967
+3,247
| +2% | +$53.7K | ﹤0.01% | 1654 |
|
|
2018
Q2 | $2.79M | Buy |
182,720
+53,820
| +42% | +$1.01M | ﹤0.01% | 1710 |
|
|
2018
Q1 | $2.54M | Sell |
128,900
-51,869
| -29% | -$1.07M | ﹤0.01% | 1707 |
|
|
2017
Q4 | $2.83M | Buy |
+180,769
| New | +$3.25M | ﹤0.01% | 1705 |
|
Other funds holding DNLI
Principal Financial Group's DNLI Position: Q2 2026 in Review
Principal Financial Group reduced its Denali Therapeutics (DNLI) stake by 4% in Q2 2026, selling an estimated $1.2M and leaving 1,420,083 shares worth $36.5M. The position accounts for 0.02% of the portfolio, ranked #647.
Principal Financial Group first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Principal Financial Group held 1,420,083 shares of Denali Therapeutics worth $36.5M as of Q2 2026.
- Principal Financial Group sold 58,403 Denali Therapeutics shares in Q2 2026, an estimated $1.2M.
- Denali Therapeutics made up 0.02% of Principal Financial Group's portfolio in Q2 2026, its #647 holding.
- Principal Financial Group first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.